
India Glycols Q2 FY27 Revenue ₹358.18 Cr Post Demerger
India Glycols Limited announced its unaudited standalone financial results for Q2 FY27 and H1 FY27, reflecting continuing operations post-demerger of its Spirits & Biofuel and Biopharma undertakings. For Q2 FY27, revenue from operations stood at ₹358.18 crore, a significant decrease from ₹2,410.71 crore in Q2 FY26 due to the demerger. EBITDA was ₹39.34 crore (vs. ₹160.25 crore in Q2 FY26), and PAT was ₹11.24 crore (vs. ₹53.94 crore in Q2 FY26). For H1 FY27, revenue was ₹712.82 crore (vs. ₹4,913.74 crore in H1 FY26), EBITDA was ₹79.55 crore (vs. ₹309.51 crore in H1 FY26), and PAT was ₹23.59 crore (vs. ₹106.79 crore in H1 FY26). The CEO highlighted the demerger as a step towards a sharper focus on bio-based specialty and performance chemicals.
Key Highlights
- Q2 FY27 revenue ₹358.18 Cr, impacted by demerger.
- EBITDA for Q2 FY27 at ₹39.34 Cr, PAT at ₹11.24 Cr.
- H1 FY27 revenue ₹712.82 Cr, EBITDA ₹79.55 Cr, PAT ₹23.59 Cr.
- Results reflect continuing operations post demerger of Spirits & Biofuel, Biopharma units.
- Company aims for sharper focus on bio-based specialty and performance chemicals.
Price Impact
More from INDIAGLYCO